Circulating Neutrophil Profiles Undergo a Dynamic Shift during Metabolic Dysfunction-Associated Steatohepatitis (MASH) Progression

被引:1
|
作者
Maretti-Mira, Ana C. [1 ]
Salomon, Matthew P. [1 ]
Chopra, Shefali [2 ]
Yuan, Liyun [1 ]
Golden-Mason, Lucy [1 ]
机构
[1] Univ Southern Calif, USC Res Ctr Liver Dis, Dept Med, Div Gastrointestinal & Liver Dis,Keck Sch Med, Los Angeles, CA 90033 USA
[2] Univ Southern Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90033 USA
基金
美国国家卫生研究院;
关键词
metabolic dysfunction-associated steatotic liver disease (MASLD); innate immunity; transcriptomics; inflammation; metabolic dysfunction-associated steatohepatitis (MASH); neutrophils; FATTY LIVER-DISEASE; INNATE; CELLS; INFLAMMATION; MACROPHAGES; FIBROSIS; PROMOTES; BURDEN; SERVER; NAFLD;
D O I
10.3390/biomedicines12051105
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Neutrophils play a crucial role in host defense against infection. Aberrant neutrophil activation may induce tissue damage via sterile inflammation. Neutrophil accumulation has been identified as a feature of the inflammatory response observed in metabolic dysfunction-associated steatohepatitis (MASH) and has been associated with liver fibrosis and cirrhosis. Here, we performed the transcriptomic analysis of circulating neutrophils from mild and advanced MASH patients to identify the potential mechanism behind neutrophil contribution to MASH progression. Our findings demonstrated that circulating neutrophils from mild and advanced MASH display an increased activated transcriptional program, with the expression of pro-inflammatory factors and an amplified lifespan compared to cells from non-diseased controls. Our results also suggest that MASH progression is associated with a dynamic shift in the profile of circulating neutrophils. In the early stages of MASH, mature neutrophils predominate in the bloodstream. As hepatic inflammation and fibrosis progress, the premature release of immature neutrophils into the circulation occurs. These immature neutrophils exhibit a pro-inflammatory profile that may exacerbate inflammation and promote fibrosis in MASH.
引用
收藏
页数:14
相关论文
共 50 条
  • [21] Denifanstat for the treatment of metabolic dysfunction-associated steatohepatitis
    Li, Xincheng
    Ayada, Ibrahim
    Li, Pengfei
    Pan, Qiuwei
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2025, 10 (02): : 108 - 109
  • [22] Expanding the armamentarium for metabolic dysfunction-associated steatohepatitis
    Francque, Sven M.
    Vonghia, Luisa
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2024, 9 (12): : 1066 - 1067
  • [23] Resmetirom (Rezdiffra) for Metabolic Dysfunction-Associated Steatohepatitis
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2024, 66 (1701):
  • [24] Prediction of metabolic dysfunction-associated steatohepatitis resolution
    Loomba, Rohit
    Amangurbanova, Maral
    Bettencourt, Ricki
    Madamba, Egbert
    Siddiqi, Harris
    Richards, Lisa
    Gottwald, Mildred D.
    Feng, Shibao
    Margalit, Maya
    Huang, Daniel
    JOURNAL OF HEPATOLOGY, 2024, 80 : S522 - S523
  • [25] Role of Saroglitazar in the treatment of metabolic dysfunction-associated steatohepatitis (MASH) in nondiabetic patients: a prospective observational study
    Kumar, Jata Shankar
    Bhardwaz, Priyanshu
    Kar, Premashis
    JOURNAL OF HEPATOLOGY, 2024, 80 : S609 - S610
  • [26] Focused Recommendations for the Management of Metabolic Dysfunction-Associated Steatohepatitis (MASH) by Advanced Practice Providers in the United States
    Lam, Brian P.
    Bartholomew, Jessica
    Bau, Sherona
    Gilles, Hochong
    Keller, Andrea
    Moore, Ann
    Nader, Khalil
    Richards, Lisa
    Henry, Linda
    Younossi, Zobair M.
    JOURNAL OF CLINICAL GASTROENTEROLOGY, 2025, 59 (04) : 298 - 309
  • [27] MACHINE LEARNING MODELS FOR PREDICTING METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) IN THE GENERAL UNITED STATES POPULATION
    Khalid, J.
    Aparasu, R. R.
    VALUE IN HEALTH, 2024, 27 (06) : S268 - S268
  • [28] Cardiovascular Risk Reduction in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis
    Bernhard, Johannes
    Galli, Lukas
    Speidl, Walter S.
    Krychtiuk, Konstantin A.
    CURRENT CARDIOLOGY REPORTS, 2025, 27 (01)
  • [29] Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis: The Patient and Physician Perspective
    Eskridge, Wayne
    Cryer, Donna R.
    Schattenberg, Joern M.
    Gastaldelli, Amalia
    Malhi, Harmeet
    Allen, Alina M.
    Noureddin, Mazen
    Sanyal, Arun J.
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (19)
  • [30] Metabolic dysfunction associated steatohepatitis (MASH) disease progression phenotyping features based on medical claims
    Berberova, Magda
    Nikolov, Petar
    Kumar, Deepa
    Lu, Liuqiang
    JOURNAL OF HEPATOLOGY, 2024, 80 : S485 - S485